Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer

NCT04596150 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

125

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasms
Breast Neoplasms
Breast Neoplasms, Triple-Negative
Breast Cancer
Breast Neoplasms, Hormone Receptor Positive/HER2 Negative

Interventions

DRUG: CX-2009
DRUG: CX-072

Sponsor

CytomX Therapeutics